Many factors contribute to the onset of insomnia. However, few studies have identiˆed the factors related to the onset of insomnia in hypertensive patients. We conducted a pharmacoepidemiologic study to examine the incidence of insomnia in hypertensive patients by using a post-marketing surveillance database. The insomnia onset was deˆned as the time ofˆrst prescription of hypnotics. The insomnia incidence rate in hypertensive patients under antihypertensive therapy was 0.77/100 person-years. The median insomnia onset date was 5 weeks. The insomnia type in 50.2％ of the patients was di‹culty in initiating sleep. We assessed the factors contributing to insomnia by using a nested case-control design. We selected 10 time-matched controls for every case. The hypotensive eŠect induced by antihypertensive therapy on the case group was lesser than that on the control group (p＜0.01). The odds ratios (ORs) were estimated using multivariate conditional logistic regression. The factors contributing to insomnia onset were a blockers (OR, 2.38; 95％ conˆdence interval [CI], 1.14 4.98), b blockers (OR, 1.54; 95％ CI, 0.99 2.39), and calcium channel blockers (OR, 0.62; 95％ CI, 0.43 0.90) compared with angiotensin-converting enzyme inhibitors; female sex (OR, 1.76; 95％ CI, 1.27  2.44); complication of gastric/duodenal disorders (OR, 2.35; 95％ CI, 1.14 4.86) or musculoskeletal system/connective tissue disorders (OR, 2.43; 95％ CI, 1.23 4.79); and concomitant antihypertensive therapy (OR, 0.44; 95％ CI, 0.31 0.63). This study identiˆed the potential factors that may help to predict insomnia onset in hypertensive patients under antihypertensive therapy.

